Shelf-stable mRNA delivery system targets bladder cancer cells without immune response

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University improves upon traditional methods of targeting bladder cancer cells with messenger RNA (mRNA) therapies.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup